XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.1

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2023

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Stock Based Compensation for Employees and Non Employees

Under each of the legal entity’s equity plans, we recorded stock-based compensation in the following expense categories in our condensed consolidated statements of operations for employees and non-employees:

		Three Months Ended March 31, 2023
		BridgeBio Equity Plan				Other Subsidiaries Equity Plan				Total
		(in thousands)
Research and development		$	11,737			$	42			$	11,779
Selling, general and administrative			11,698				—				11,698
Restructuring, impairment and related charges			—				—				—
Total stock-based compensation		$	23,435			$	42			$	23,477

		Three Months Ended March 31, 2022
		BridgeBio Equity Plan					Other Subsidiaries Equity Plan				Total
		(in thousands)
Research and development		$	8,486				$	71			$	8,557
Selling, general and administrative			14,523					29				14,552
Restructuring, impairment and related charges			1,172					—				1,172
Total stock-based compensation		$	24,181				$	100			$	24,281

Summary of Stock Option Activity

The following table summarizes BridgeBio’s stock option activity under the Plans for the three months ended March 31, 2023:

	Options Outstanding								Weighted- Average Exercise Price per Option				Weighted- Average Remaining Contractual Life (years)				Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2022						11,637,861
Regular equity program		9,811,936							$	28.00				7.7			$	—
Eidos Awards Exchange		1,445,885							$	14.96				5.9			$	1,427
Exchange Program		380,040							$	2.35				6.2			$	2,246
Granted						1,106,897
Regular equity program		1,106,897							$	11.48
Exercised						(44,464	)
Eidos Awards Exchange		(5,776	)						$	11.82
Exchange Program		(38,688	)						$	3.22
Cancelled						(437,941	)
Regular equity program		(434,179	)						$	23.90
Eidos Awards Exchange		(1,852	)						$	19.75
Exchange Program		(1,910	)						$	4.03
Outstanding as of March 31, 2023						12,262,353
Regular equity program		10,484,654							$	26.43				7.6			$	15,878
Eidos Awards Exchange		1,438,257							$	14.96				5.5			$	7,445
Exchange Program		339,442							$	2.24				6.1			$	5,040
Exercisable as of March 31, 2023						7,456,207
Regular equity program		5,832,486							$	27.68				6.6			$	102
Eidos Awards Exchange		1,289,387							$	13.75				5.4			$	7,425
Exchange Program		334,334							$	2.18				6.0			$	4,977

Summary of Restricted Stock Units Activity

The following table summarizes BridgeBio’s RSU activity under the Plans for the three months ended March 31, 2023:

		Unvested Shares of RSUs Outstanding				Weighted- Average Grant Date Fair Value
Balance as of December 31, 2022			4,108,642			$	21.60
Granted			7,532,921			$	11.78
Vested			(595,613	)		$	17.86
Cancelled			(167,085	)		$	19.56
Balance as of March 31, 2023			10,878,865			$	15.04

Summary of Restricted Stock Award Activity

The following table summarizes our RSA activity under the Plans for the three months ended March 31, 2023:

		Unvested Shares of RSAs Outstanding				Weighted- Average Grant Date Fair Value
Balance as of December 31, 2022			652,058			$	7.29
Granted — Exchange Program			194,350			$	18.55
Vested — Exchange Program			(194,350	)		$	18.55
Vested — Regular equity program			(144,891	)		$	7.16
Cancelled — Regular equity program			—			$	-
Balance as of March 31, 2023			507,167			$	7.33

2019 Employee Stock Purchase Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Schedule of Assumptions Used to Determine Fair Value of Stock Purchase Rights

We used the Black-Scholes model to estimate the fair value of stock options and stock purchase rights under the ESPP. For the three months ended March 31, 2023, we used the following weighted-average assumptions in the Black-Scholes calculations:

	Stock Options				ESPP
Expected term (in years)	6.00 - 6.02					0.50
Expected volatility	66.23% - 66.34%				86.12% - 113.19%
Risk-free interest rate	3.90% - 4.12%				3.12% - 4.98%
Dividend yield		—				—
Weighted-average fair value of stock-based awards granted	$	7.25			$	5.54

Restricted Stock Awards

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Stock Based Compensation for Employees and Non Employees

For the three months ended March 31, 2023, we recognized stock-based compensation expense related to RSAs under the Plans as follows:

		Three Months Ended March 31,
		2023				2022
		(in thousands)
Exchange Program		$	3,605			$	—
Other RSAs			1,026				1,485
Total stock-based compensation    expense		$	4,631			$	1,485

X

- Definition

Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the changes in outstanding nonvested restricted stock units.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_PlanNameAxis=bbio_TwoThousandNineteenEmployeeStockPurchasePlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: